These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9690201)

  • 1. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy.
    Benigni A; Corna D; Maffi R; Benedetti G; Zoja C; Remuzzi G
    Kidney Int; 1998 Aug; 54(2):353-9. PubMed ID: 9690201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
    Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G
    Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
    Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
    Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury.
    Zoja C; Corna D; Bruzzi I; Foglieni C; Bertani T; Remuzzi G; Benigni A
    Exp Nephrol; 1996; 4(4):213-21. PubMed ID: 8983642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis.
    Zoja C; Benigni A; Camozzi D; Corna D; Longaretti L; Todeschini M; Remuzzi G
    Kidney Int; 2003 Sep; 64(3):857-63. PubMed ID: 12911535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy.
    Zoja C; Liu XH; Abbate M; Corna D; Schiffrin EL; Remuzzi G; Benigni A
    Exp Nephrol; 1998; 6(2):121-31. PubMed ID: 9567218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat.
    Hofman C; Gabai E; Peleg E; Munter K; Rosenthal T
    Blood Press; 2005; 14(2):114-9. PubMed ID: 16036489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
    Dhein S; Hochreuther S; Aus Dem Spring C; Bollig K; Hufnagel C; Raschack M
    J Pharmacol Exp Ther; 2000 May; 293(2):351-9. PubMed ID: 10773002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant nephropathy in a 'Fisher-to-Lewis' rat model.
    Adams J; Odoni G; Ogata H; Viedt C; Amann K; Ritz E; Orth SR
    Nephrol Dial Transplant; 2002 May; 17(5):780-7. PubMed ID: 11981063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.
    Gross ML; Ritz E; Schoof A; Helmke B; Parkman A; Tulp O; Münter K; Amann K
    Lab Invest; 2003 Sep; 83(9):1267-77. PubMed ID: 13679434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
    Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
    Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.
    Zoja C; Corna D; Camozzi D; Cattaneo D; Rottoli D; Batani C; Zanchi C; Abbate M; Remuzzi G
    J Am Soc Nephrol; 2002 Dec; 13(12):2898-908. PubMed ID: 12444208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models.
    Orth SR; Odoni G; Karkoszka H; Ogata H; Viedt C; Amann K; Ferrari P; Ritz E
    Nephrol Dial Transplant; 2003 Jan; 18(1):62-9. PubMed ID: 12480961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin receptor A blockade reduces proteinuria and vascular hypertrophy in spontaneously hypertensive rats on high-salt diet in a blood-pressure-independent manner.
    Trenkner J; Priem F; Bauer C; Neumayer HH; Raschak M; Hocher B
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():385S-388S. PubMed ID: 12193128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibition and endothelin antagonism for endothelial dysfunction in heart failure: mono-or combination therapy.
    Bauersachs J; Fraccarollo D; Schäfer A; Ertl G
    J Cardiovasc Pharmacol; 2002 Oct; 40(4):594-600. PubMed ID: 12352322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
    Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation.
    Nabokov A; Amann K; Wagner J; Gehlen F; Münter K; Ritz E
    Nephrol Dial Transplant; 1996 Mar; 11(3):514-20. PubMed ID: 8671823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism.
    Hocher B; Lun A; Priem F; Neumayer HH; Raschack M
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S492-5. PubMed ID: 9595522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat.
    Ezra-Nimni O; Ezra D; Peleg E; Munter K; Rosenthal T
    Am J Hypertens; 2003 Apr; 16(4):324-8. PubMed ID: 12670751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.